Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP RA and Cagrilintide in Overweight or Obesity
NCT07411560Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2026
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0480-0389 in Overweight and obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Number of Treatment Emergent Adverse Events (TEAEs) nausea, vomiting and diarrhoea. Started Feb 2026; status: recruiting.
02
Drugs
NNC0480-0389
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT07411560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07411560.